CH Biotech R&D Co., Ltd. AI Stock Analysis
CH Biotech R&D Co., Ltd. (6534) AI Stock Analysis
CH Biotech R&D Co., Ltd.
(TWSE:6534)
CH Biotech earns an above-average score driven by a financially sound profile: strong multi-year revenue growth, premium margins, a deleveraged equity-heavy balance sheet and restored free cash flow. Valuation adds support, with a modest 15.4x P/E and a high 6.2% dividend yield. The score is held back by weak technicals — the stock trades below all key moving averages with negative MACD and deeply depressed momentum readings — and by the fundamental watch item of margin compression that has left net income flat for four consecutive years despite rising revenue.
CH Biotech R&D Co., Ltd. (6534) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 8.62B
- Dividend Yield
- 6.17%
- Average Volume (3M)
- 59.46K
- Price to Earnings (P/E)
- 15.2
- Beta (1Y)
- 0.07
- Revenue Growth
- 6.31%
- EPS Growth
- 31.07%
- Country
- TW
- Employees
- 200
- Sector
- General
- Sector Strength
- 55
- Industry
- Agricultural Inputs
CH Biotech R&D Co., Ltd. Business Overview & Revenue Model
Company Description
CH Biotech R&D Co., Ltd. is a company dedicated to the creation and worldwide supply of agricultural chemicals rooted in biotechnology. Their commercial footprint spans Taiwan, the United States, Canada, Australia, Brazil, Argentina, Uruguay, and Chi...
CH Biotech R&D Co., Ltd. Financial Statement Overview
Summary
Fundamentals are the company's core strength. Revenue has nearly tripled since 2020 to NT$1.82 billion (+11% in the latest year) with premium industry margins (74.5% gross, 34.3% operating). The balance sheet is conservative — debt cut to NT$664 million and debt-to-equity down to 0.25, with equity funding roughly three-quarters of assets and ROE of 17.3%. Cash flow recovered strongly, with free cash flow swinging back to a positive NT$466 million covering 79% of net income. Offsetting these strengths: gross margin compressed sharply from 83.4% to 74.5%, net margin slipped to 25.5%, and net income has been flat near NT$460–476 million for four years, while capital spending cycles make free cash flow lumpy.
Income Statement
72PositiveBalance Sheet
82Very PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.87B | 1.82B | 1.64B | 1.51B | 1.43B | 1.02B |
| Gross Profit | 1.53B | 1.36B | 1.36B | 1.26B | 1.13B | 847.95M |
| EBITDA | 879.00M | 837.25M | 797.71M | 761.56M | 722.29M | 470.20M |
| Net Income | 604.68M | 463.79M | 476.39M | 463.29M | 465.42M | 291.50M |
Balance Sheet | ||||||
| Total Assets | 3.81B | 3.57B | 3.63B | 3.65B | 3.20B | 3.03B |
| Cash, Cash Equivalents and Short-Term Investments | 640.73M | 397.27M | 482.13M | 943.00M | 533.10M | 326.79M |
| Total Debt | 868.36M | 664.33M | 747.33M | 845.16M | 894.89M | 1.12B |
| Total Liabilities | 1.17B | 888.48M | 982.44M | 1.13B | 1.11B | 1.31B |
| Stockholders Equity | 2.63B | 2.69B | 2.65B | 2.52B | 2.09B | 1.72B |
Cash Flow | ||||||
| Free Cash Flow | 741.37M | 465.68M | -51.51M | 542.89M | 581.35M | 192.43M |
| Operating Cash Flow | 897.01M | 589.02M | 538.44M | 659.15M | 698.97M | 264.36M |
| Investing Cash Flow | -159.93M | -141.52M | -594.77M | -142.89M | -117.22M | -44.75M |
| Financing Cash Flow | -727.25M | -530.39M | -406.21M | -106.60M | -375.37M | -222.06M |
CH Biotech R&D Co., Ltd. Peers Comparison
Overall Rating
TW:416270Outperform- TW:653467Neutral
TW:416954Neutral
TW:412844Neutral
TW:654143Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4162 | 70Outperform | TWD 7.43B | 14.16 | ― | 3.79% | -58.69% | -66.96% |
| TW:6534 | 67Neutral | TWD 8.35B | 15.17 | ― | 6.17% | 6.31% | 31.07% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4169 | 54Neutral | TWD 7.93B | -301.25 | ― | 0.27% | ― | ― |
| TW:4128 | 44Neutral | TWD 7.85B | 14.95 | ― | ― | 4.85% | ― |
| TW:6541 | 43Neutral | TWD 7.47B | -5.00 | -26.61% | ― | 492.43% | 21.57% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6534 | CH Biotech R&D Co., Ltd. | 86.00 | -1.37 | -1.57% | |
| TW:6541 | Tanvex Biopharma | 28.15 | -27.55 | -49.46% | |
| TW:4128 | Microbio Co., Ltd. | 13.55 | -7.25 | -34.86% | |
| TW:4162 | PharmaEngine, Inc. | 52.80 | -16.88 | -24.23% | |
| TW:4169 | TCM Biotech International Corp. | 120.50 | -60.77 | -33.52% | |
| TW:7832 | Intelligene Inc | 13.15 | 0.85 | 6.91% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026